Erratum to neoadjuvant chemo-immunotherapy for lung cancer: how much is too much?

This article (1) titled “Neoadjuvant chemo-immunotherapy for lung cancer: how much is too much?” (doi: 10.21037/tlcr-22-828), unfortunately contains a few errors in the Funding and Conflicts of Interest statements. The corrections can be found below.

The funding statement should be changed from “Funding: None.” to “Funding: This work was supported in part by National Cancer Institute of the National Institute of Health Research Project Grant (R01CA234629), the AACR-Johnson & Johnson Lung Cancer Innovation Science Grant (18-90-52-ZHAN), the MD Anderson Physician Scientist Program.”.

The Conflicts of Interest statement should be changed from “Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-22-828/coif). The authors have no conflicts of interest to declare.” to “Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at https://tlcr.amegroups.com/article/view/10.21037/tlcr-22-828/coif). JJZ serves as an unpaid editorial board member of Translational Lung Cancer Research from October 2021 to September 2023. JJZ was supported by the National Cancer Institute of the National Institute of Health Research Project Grant (R01CA234629), the AACR-Johnson & Johnson Lung Cancer Innovation Science Grant (18-90-52-ZHAN), the MD Anderson Physician Scientist Program. JJZ reports consulting fees from Johnson and Johnson, personal fees from Novartis, Bristol Myers Squibb, AstraZeneca, GenePlus, Innovent and Hengrui, serves on board for Novartis, AstraZeneca, GenePlus, and received support from Novartis, Johnson and Johnson. ND has no conflicts of interest to declare.”.

Following this change, the COI form was updated.

The authors apologize for the oversight.

Click here to view the updated version of the article.